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Abstract 
 
Despite emergence of new systemic therapies, metastatic melanoma remains a challenging and often 
fatal form of skin cancer. The renin-angiotensin system (RAS) is a major physiological regulatory 
pathway controlling salt-water equilibrium, intravascular volume and blood pressure. Biological 
effects of the RAS are mediated by the vasoactive hormone angiotensin II (AngII) via two receptor 
subtypes, AT1R (encoded by AGTR1) and AT2R (encoded by AGTR2). We report decreasing 
expression and increasing CpG island methylation of AGTR1 in metastatic versus primary 
melanoma and detection in serum of methylated genomic DNA from the AGTR1 CpG island in 
metastatic melanoma implying that AGTR1 encodes a tumour suppressor function in melanoma. 
Consistent with this hypothesis, antagonism of AT1R using losartan or shRNA-mediated knock-
down in melanoma cell lines expressing AGTR1 resulted in acquisition of the ability to proliferate in 
serum-free conditions. Conversely, ectopic expression of AGTR1 in cell lines lacking endogenous 
expression inhibits proliferation irrespective of the presence of AngII implying a ligand-independent 
suppressor function for AT1R. Treatment of melanoma cell lines expressing endogenous AT2R with 
either AngII or the AT2R-selective agonist Y6AII induces proliferation in serum-free conditions 
whereas the AT2R-specific antagonists PD123319 and EMA401 inhibit melanoma growth and 
angiogenesis and potentiate inhibitors of BRAF and MEK in cells with BRAF V600 mutations. Our 
results demonstrate that the RAS has both oncogenic and tumour suppressor functions in melanoma. 
Pharmacological inhibition of AT2R may provide therapeutic opportunities in melanomas expressing 
this receptor and AGTR1 CpG island methylation in serum may serve as a novel biomarker of 
metastatic melanoma. 
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Introduction 
 
Stage IV (metastatic) melanoma frequently presents as large volume, multi-focal disease often with 
central nervous system (CNS) involvement, with at least 40% of melanoma patients developing brain 
metastases. Recent therapeutic advances have improved outcomes for some patients with advanced 
melanoma. These include the use of targeted agents such as the BRAF and MEK kinase inhibitors in 
patients whose melanomas contain mutations in BRAF and NRAS and immunotherapy with the anti-
CTLA4 antibody ipilimumab (1, 2, 3, 4, 5) and anti-PD-1 agents such as nivolumab and 
pembrolizumab (6, 7). Despite the introduction of these new approaches to clinical practice, many 
patients continue to have poor outcomes and there remains a clear need for both novel therapeutic 
strategies as well as serum biomarkers to inform adjuvant or earlier treatment with immunotherapy. 
The renin-angiotensin system (RAS) is a key physiological pathway involved in intravascular 
volume regulation. Angiotensin II (AngII) an octapeptide hormone is the biological effector and key 
player with important functions in maintenance of salt-water balance, blood pressure control and 
other fundamental biological pathways. The effects of AngII are mediated through two G protein 
coupled receptors, the AT1R (encoded by AGTR1) and AT2R (encoded by AGTR2). Activation of the 
receptors is thought in some systems to have opposing effects (8). Relatively little is known of the 
involvement of the RAS in cancer. However, a small subset of oestrogen receptor (ER) positive and 
HER2 negative breast cancers over-express AT1R and their growth can be partially inhibited by the 
selective AT1R antagonist losartan commonly used as an anti-hypertensive agent (9, 10, 11). 
Consistent with these observations, down-regulation of AGTR1 by the miRNA miR-410 suppresses 
growth, invasiveness, angiogenesis and migration of pancreatic cancer cells, suggesting that AT1R 
may also have oncogenic properties in pancreatic cancer (12). In melanoma, inhibition of 
angiogenesis by losartan was observed in a murine model (13) but no studies have been carried out 
in human melanoma and the associated function of AT2R signalling remains unexplored. 
Previous studies have identified an array of genes subjected to methylation-dependent transcriptional 
silencing in melanoma. Furthermore, detection of methylated genomic DNA in peripheral blood is an 
attractive potential source of cancer biomarkers because of the stability of DNA and the relative 
specificity of methylation for malignant disease (14). The requirement for sensitive and specific 
biomarkers of recurrent and particularly unresectable/metastatic melanoma has been emphasised by 
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evidence from recent clinical trials that efficacy of anti-melanoma therapies is superior, with 
improved clinical outcomes, when such drugs are deployed in low volume disease (15). We 
previously showed that serum detection of methylated genomic DNA from TFPI2 is associated with 
metastatic melanoma (16) and others have also shown the utility of this approach (17, 18). Herein, 
we explored the involvement of the two principal angiotensin receptors in melanoma and 
demonstrate the potential to exploit RAS alteration both for therapeutic and diagnostic purposes. 
 
Results 
 
Expression of AGTR1 and AGTR2 in melanoma cell lines 
 
We analysed the expression of AGTR1 and AGTR2 in a panel of melanoma cell lines arising 
respectively from radial growth phase (RGP; PMWK, WM35, SBCL2), vertical growth phase (VGP; 
WM902.B (in figure 1A it is WM902.6), SKMEL224, MEL505 and metastatic melanoma 
(WM266.4, SKMEL2, SKMEL23, SKMEL30, SKMEL147, SKMEL173, SKMEL501, COLO829, 
A375). AGTR1 mRNA was detectable in normal human melanocytes and in each of the RGP cell 
lines, with the highest expression in PMWK but was greatly down regulated in the WM902B VGP 
cell line (Figure 1A) and undetectable in SKMEL224 and MEL505. In metastatic melanoma cell 
lines, expression was undetectable in SKMEL23, WM266.4, SKMEL2 and A375M and greatly 
down-regulated in SKMEL30 and COLO829 (Fig 1A). Although expressed at lower levels than 
AGTR1, AGTR2 mRNA was nonetheless detectable in most cell lines with the exception of SKMEL2 
and SKMEL224 where there was no detectable expression.  Highest expression was observed in 
PMWK, WM35, MEL505, COLO829 and SKMEL23 (Figure 1A). We also determined whether 
expression of AGTR1 and AGTR2 was affected by serum-free conditions. PMWK, SKMEL23 and 
SKMEL224 cells were grown in serum-free conditions and mRNA was harvested at various time 
points and analysedfor AGTR1 and AGTR2 expression by qPCR. No change in expression of either 
gene was detected up to 48 hours (data not shown). 
 
AGTR1 silencing occurs in melanoma cell lines via CpG island methylation 
 
Expression analysis revealed down-regulation of AGTR1 in multiple VGP and metastatic melanoma 
cell lines (Figure 1A). We wished to explore the mechanistic basis for this observation. A CpG island 
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is located in the 5´ regulatory sequences of AGTR1 and we performed pyrosequencing to measure 
methylation in the cell line panel. Representative pyrograms are shown in Figure 1B and methylation 
density profiles are presented in Figure 1C. In normal melanocytes, each of the 7 analysed 
methylation variable positions (MVP) was entirely unmethylated (Figure 1C). In contrast, we 
observed dense methylation in several of the melanoma cell lines (Figure 1C; Table 1). Of note, the 
majority of cell lines with dense AGTR1 CpG island methylation were VGP and metastatic 
melanomas whereas the RGP cell lines PMWK, SBCL2 and WM35 all showed only low level 
methylation. In general, there was a good correlation between methylation and transcriptional 
silencing of AGTR1. To further confirm that CpG island methylation causes silencing of AGTR1, 
PMWK, SKMEL23 and SKMEL224 cells were grown in the presence or absence of the 
demethylating agent 5’-azacytidine. 5’-Azacytidine had no effect on AGTR1mRNA levels in PMWK 
cells (CpG island unmethylated) but resulted in increased levels in SKMEL23 and SKMEL224 (CpG 
island methylated) (Figure 1D). Addition of the HDAC inhibitor Trichostatin A (TSA) caused a 
further increase in AGTR1 mRNA levels in SKMEL23 and SKMEL224 (Figure 1D). 
 
AGTR1 is down regulated by CpG island methylation in metastatic melanoma 
 
Together, the above data imply that AT1R may have tumour suppressor function in melanoma and 
suggests that inactivation of AGTR1 via CpG island methylation occurs as a late event in melanoma. 
To validate this hypothesis in clinical tumour samples, we tested a series of paired primary and 
metastatic melanomas  together with control benign nevi for AGTR1 expression and CpG island 
methylation using qPCR. AGTR1 was readily detectable using qPCR in control benign nevi. 
Expression was typically greatly down regulated in metastatic melanomas relative to matched 
primary and frequently undetectable in the metastasis (Figure 2A). We then tested AGTR1 CpG 
island methylation in primary and metastatic melanomas, again using histologically confirmed 
benign pigmented nevi as controls. Representative pyrograms are shown in Figure 2B. In each of the 
benign nevi the AGTR1 CpG island was unmethylated or methylated at a very low level showing that 
methylation is a feature of malignant melanocytes (N1-N8, Figure 2C). Similarly, in a series of 
primary melanomas with a Breslow thickness (BT) of 1mm or less which had not metastasised, the 
CpG island was invariably unmethylated (P1-P10, Figure 2C). In contrast, in primary melanomas 
from which metastatic disease subsequently developed, there was a clear increase in methylation 
compared to low-risk melanomas (P11-P16, Figure 2C). Moreover, in 5/6 cases where matched 
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primary and metastasis was available, methylation increased from the primary to the metastatic 
lesion (P11-P16 and M11-M16, Figure 2C). 
 
AGTR1 CpG island methylation is a serum biomarker of metastatic melanoma 
 
The association of AGTR1 CpG island methylation with metastatic melanoma prompted us to 
explore whether methylated genomic DNA from the AGTR1 CpG island is detectable in peripheral 
blood samples of patients with melanoma. We analysed a cohort of sera from 63 patients with (13) or 
without (50) distant metastatic disease and as controls we used sera from healthy individuals. Serum 
was isolated using a standardised protocol and methylation in the AGTR1 CpG island analysed using 
pyrosequencing. Representative methylation profiles indicating the % methylation at each of the 7 
MVPs in the analysed fragment are shown in Figure 2D wherein the increased methylation levels 
present in sera from patients with metastatic disease are clearly evident. Methylated genomic DNA 
from AGTR1 was not detected in the serum of healthy controls. However, positivity for detection of 
methylated AGTR1 (defined as % methylation of  5 at 3 or more MVPs) was significantly higher in 
patients with metastatic disease (bone, lung liver, spleen) than in those without metastases: 7/13 
(54%) vs 6/50 (12%), p=0.0058.  
 
Down-regulation of AGTR1 with over-expression of AGTR2 in melanoma CNS metastases 
 
Central nervous system (CNS) metastasis is a common event in melanoma patients. Given the 
relationship implied between loss of AGTR1and development of metastatic melanoma, we were 
interested therefore to examine the potential involvement of the RAS in CNS metastasis and to 
determine the expression patterns of AGTR1 and AGTR2. To address this, we generated four novel 
CNS metastatic melanoma cell lines de novo from tissue obtained at surgical resection of intra-
cranial metastases confirmed by histopathology to be metastatic melanoma and expression of AGTR1 
and AGTR2 was determined by qPCR in early passage cells. AGTR1 was expressed in one cell line 
but was undetectable in the other 3 (Figure 2E). In contrast, AGTR2 was expressed in 3/4 melanoma 
brain metastasis cell lines but was not expressed in control brain tissue (Figure 2E).  
 
Antagonism of AT1R confers serum independence to melanoma cell lines 
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Transcriptional silencing of AGTR1 implies a tumour suppressor rather than oncogenic function for 
AGTR1 in melanoma. To seek mechanistic evidence to support this hypothesis, we investigated the 
effect of antagonism of AT1R. Since expression of AGTR1 was highest in PMWK and SKMEL147 
(Figure 1A), we selected these cell lines to initially assess the effect of antagonism using the 
selective AT1R blocker losartan. In serum replete conditions, losartan had no effect as both cell lines 
readily proliferated. However, in serum free conditions an increase in proliferation was observed in 
both cell lines on day 3 and day 5 in the presence of losartan (Figure 3A and 3B). Promotion of 
PMWK and SKMEL147 proliferation by losartan was reproducibly observed in multiple 
independent experiments (PMWK: p=0.0066, SKMEL147: P=0.005). To confirm the specificity of 
the effect of losartan on proliferation we tested SKMEL224 cells that do not express AGTR1. These 
cells grew readily in serum-free conditions and growth was unaffected by the addition of Losartan in 
contrast to the clear growth promoting effect of losartan on PMWK cells (Figure 3C). Similarly, 
losartan had no effect on the proliferation of MEL505 and SKMEL30 that also lack expression of 
AGTR1 but promoted serum-free growth of C8161and SKMEL173 both of which express AGTR1 
(data not shown). We conclude, therefore, that the ability of losartan to promote melanoma growth 
requires expression of AGTR1. 
 
Loss of AT1R confers growth factor independence in melanoma 
 
Rather than acting as an oncogenic receptor (as reported in a subset of breast and other cancers), our 
results imply a negative growth regulatory function for AT1R in melanoma. To further examine the 
association between the absence of AT1R and serum-free growth in melanoma we used inhibitory 
RNA to modulate expression of AGTR1. We generated stable knockdowns using the TRIPZ 
Inducible Lentiviral shRNA vector system (Dharmacon) that allows reversible, controlled gene 
silencing. The vector is designed to be Tet-On® such that shRNA expression is induced in the 
presence of doxycycline. PMWK cells stably expressing the AGTR1 shRNA vector or the non-
silencing control vector were cultured in 10% FBS, 2% FBS and 1% FBS conditions in the presence 
or absence of doxycycline. Doxycycline was added at 2g/ml daily for the course of the experiment 
to maintain AGTR1 knockdown. Knockdown of AGTR1 was confirmed by qPCR and western 
blotting (Figure 4A, upper panels). Proliferation of cells was assessed on day 5. All cells maintained 
in 10% serum were able to proliferate in the presence or absence of doxycycline (Figure 4A, lower 
panels).  However, in 1% serum conditions, PMWK cells expressing AGTR1 shRNA grew more 
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efficiently in the presence of doxycycline (where AGTR1 is knocked down) than in its absence and 
more efficiently than the non-silencing cells in both conditions (p<0.05; Figure 4B). These data show 
that even modest decreases in levels of AGTR1 result in enhanced proliferation in conditions of 
growth factor limitation.  
 
AGTR1 is a ligand independent suppressor of melanoma growth 
 
Next, we examined the effect of ectopic expression of AGTR1 in cells that lack endogenous 
expression of the gene. We transfected the AGTR1 null cell line SKMEL224 with escalating 
concentrations of AGTR1 expression plasmid or control plasmid (0.1g -1g) and selected 
transfectants in G418. Surviving colonies transfected with the control plasmid were obtained at 
comparable frequency in all control plasmid concentrations but no transfectants were obtained at any 
of the AGTR1 expression plasmid input concentrations (Figure 4C). Importantly, the colony 
suppressing effect of ectopically expressed AGTR1 did not require exogenous AngII. Further 
attempts to generate stable AGTR1 expressing clones in serum and serum-free conditions and using 
another null line (SKMEL23) were also unsuccessful (Figure 4C). We also performed clonogenic 
assays by transiently transfecting SKMEL224 and SKMEL23 cells in serum and serum free 
conditions as described in methods.  However, as with our previous experiments, in both serum 
conditions colonies were only obtained with the control plasmid. To rule out a potential non-specific 
toxic effect of the AGTR1 expression plasmid, we transfected the AGTR1 expressing line, PMWK 
with this plasmid and successfully generated stable clones (Figure 4C). Taken together, these results 
imply that ectopic expression of AGTR1 is detrimental to cell lines lacking expression of the 
endogenous gene and this effect is independent of AngII.  
AngII drives proliferation of melanoma cell lines expressing AT2R  
 
AngII has been shown to promote proliferation in a subset of breast cancers which overexpress AT1R 
and given the evidence of transcriptional silencing of AGTR1 in melanoma we wished to determine 
the effect of AngII on melanoma proliferation. Accordingly, we initially tested the effect of varying 
concentrations of AngII (1pM-100pM) on the proliferation of melanoma cell lines with differing 
expression of AT1R and AT2R (as determined in Figure 1A), namely PMWK (AGTR1 + / AGTR2 
+), SKMEL 224 (AGTR1 - / AGTR2 -) and SKMEL23 (AGTR1 - / AGTR2 +). Under normal 
culture conditions in media supplemented with 10% serum (non-starved) AngII had no effect on the 
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proliferation of GBM cell lines irrespective of their expression of angiotensin receptors (Figure 4D). 
Foetal bovine serum (FBS) contains an abundance of growth promoting as well as inhibitory factors 
that could mask the growth enhancing effects of angiotensin II (19). We therefore repeated this 
experiment in serum free conditions and under these conditions significant differences in growth 
were observed (Figure 4D). In serum-free medium and in the absence of AngII, PMWK and 
SKMEL23 cells proliferated minimally. However, in the presence of AngII both cell lines exhibited 
a significant dose-dependent increase in growth (PMWK: 1M, p=0.0896; 10nM, p=0.01; 100pM, 
p=0.0026; 1pM, p=0.041. SKMEL23: 1M, p=0.0288; 10nM, p=0.0372; 100pM, p=0.0185; 1pM, 
p=0.8004). The maximum growth-promoting effect occurred in both cell lines at 100pM AngII 
(Figure 4D). Essentially similar effects of AngII were also observed in SKMEL505 (AGTR1 - / 
AGTR2 +). In contrast, AngII had no effect on proliferation of SKMEL224 in serum-free medium 
(Figure 4D). These results are consistent with the growth-promoting effects of AngII being mediated 
via AT2R. To test this hypothesis, we determined the effect on melanoma cells of Y6AII which we 
recently showed to be a highly selective agonist of AT2R (20). PMWK cells were cultured in serum-
free medium in the presence or absence of varying concentrations of Y6AII and proliferation 
assessed on day 5. As shown in Figure 4E, there was a clear dose-dependent increase in proliferation 
in cells treated with Y6AII, with 100 M Y6AII causing an increase in proliferation at levels 
comparable to stimulation with 100pMAngII (Figure 5B). Y6AII caused an increase in proliferation 
of PMWK across a range of concentrations and this was maximal at10M (p=0.048) and100M 
(p=0.0003). In contrast, Y6AII had no effect on proliferation of the AGTR2 negative cell lines 
SKMEL2 and SKMEL224 (Data no shown). 
Selective blockade of AT2R inhibits melanoma growth in vitro and in vivo  
 
These results imply a role for AT2R rather than AT1R in promoting melanoma growth and prompted 
us to determine whether pharmacological inhibition of AT2R inhibits melanoma growth. We first 
evaluated the effect of PD123319 a selective, non-peptide AT2R inhibitor. In the absence of 
exogenous AngII, PD123319 had no effect on proliferation of any of the tested cell lines in either 
10% serum or serum-free conditions (Data not shown). However, PD123319 efficiently blocked the 
growth promoting effects of AngII in serum free conditions in both PMWK (p=0.05) and SKMEL23 
(p=0.0096) (Figure 5A). In SKMEL224, neither AngII nor PD123319 had any effect on proliferation 
(Figure 5A). Having observed that PD123319 inhibits melanoma cells expressing AT2R, we tested 
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the more potent EMA401, a highly selective tetrahydroisoquinoline AT2R antagonist (21). EMA401 
inhibited proliferation of PMWK cells, with almost complete inhibition at 30M in the absence of 
exogenous AngII (Figure 5B). We then wished to determine whether the ability of AT2R-blocking 
agents to inhibit melanoma was also seen in vivo. For this, we used a zebra fish model which is 
recognised as an excellent system in which to study melanoma (23,24). SKMEL23 cells were 
injected into zebrafish yolksac and the fish grown with or without 30M EMA401 in their medium. 
The presence of EMA401 greatly reduced the proliferation of the melanoma cells (Figure 5C). 
Similar inhibition of proliferation was seen in PMWK cells. 
 
Selective blockade of AT2R inhibits melanoma angiogenesis  
 
AngII signalling is known to be an important determinant of angiogenesis. We therefore sought to 
determine whether the ability of melanoma cells to promote angiogenesis is affected by selective 
blockade of AT1R and AT2R. To assess the role of angiotensin receptor signalling in the induction of 
tumour associated angiogenesis, we utilised the assay described by Carpentier et al (22). Human 
microvascular endothelial cells (hCMEC/D3) were exposed to conditioned media (CM) collected 
from PMWK or SKMEL23 cells treated with angiotensin II alone or in combination with the 
angiotensin receptor antagonists Losartan, PD123319 and EMA401. The effects on endothelial tube 
formation (master segments length) and on network integrity (number of meshes) was determined 
after 24 hours. Exposure of hCMEC/D3 cells to medium conditioned by PMWK or SKMEL23 
resulted in an increase in master segments length and tube formation. This was not potentiated by 
exposure of cells to exogenous AngII during the conditioning phase. However, both losartan and 
PD123399 blocked the increase brought about by the CM with EMA401 demonstrating superior 
efficacy (Figure 6A and 6B).  
 
Selective blockade of AT2R potentiates anti-BRAF therapy 
 
We noted that some of the cell lines with low expression of AGTR1 contained the BRAF V600 
mutation which confers sensitivity to BRAF and MEK inhibitors (A375, WM239, WM35, 
COLO829). This led us to evaluate whether inhibition of AT2R affects response to these agents. We 
tested this question in A375 and WM329 cell lines which express low to undetectable AGTR1 and 
readily detectable AGTR2  and in two further cell lines (WM164 and WM793) which express 
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AGTR2 and positive for BRAF V600 mutation. Cells were grown in medium containing 1% serum 
and challenged with various concentrations of dabrafenib with or without EMA401. As observed 
previously, PD123319 alone had no effect on proliferation of cell lines under these growth 
conditions (data not shown). However, EMA increased the sensitivity of all the tested cell lines to 
dabrafenib, implying that inhibition of AT2R increases cellular sensitivity to targeted agents in 
melanoma (Figure 6C). This is most clearly illustrated in A375 cells in which dabrafenib and 
EMA401 individually only incompletely inhibit proliferation but together produce complete 
inhibition. 
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Discussion 
  
The importance of the RAS in regulating intravascular volume is well-recognized and therapeutic 
manipulation of the RAS is a mainstay of antihypertensive and heart failure management. There is 
evidence in breast cancer that over-expressed AT1R has oncogenic function(s) (9, 10, 11), but this is 
restricted to a subset of oestrogen receptor positive HER2 negative cases in which AngII promotes 
and losartan inhibits proliferation. In the current work, we report that AngII drives proliferation of 
melanoma and to the best of our knowledge this is the first demonstration that AngII is mitogenic in 
human melanoma cells. We also provide several lines of evidence that (in contrast to the situation in 
breast cancer) AT1R acts as a tumor suppressor rather than as an oncogenic receptor and, in addition, 
AT2R acts as an oncogene in melanoma. Together, the opposing functions of AT1R and AT2R reveal 
that the RAS is a bifunctional growth regulator in melanoma. Fundamental to our investigation of the 
function(s) of AT1R and AT2R in melanoma is the use of highly selective agonists and antagonists to 
manipulate the endogenous activity of each receptor, rather than cell lines that have been engineered 
to ectopically over-express either gene. Additional work to investigate the precise mechanism by 
which AT1R acts as a tumour suppressor in melanoma is being undertaken using inducible 
expression in appropriate systems. 
 
We are not aware of previous experimental evidence implying a tumor suppressor function for AT1R 
in human malignancy but we now provide multiple, complementary lines of evidence to support the 
candidacy of AGTR1 (encoding AT1R) as a tumor suppressor in melanoma. First, antagonism of 
AT1R by losartan promotes the growth in serum-free medium of melanoma cell lines that express 
AGTR1. We first observed this effect in PMWK (RGP) melanoma cells, but also subsequently in 
SKMEL147 (metastatic), C8161 (metastatic) and other melanoma cell lines that express AGTR1. The 
effect of AT1R blockade in promoting proliferation is thus common to melanoma cell lines 
expressing ATGR1, losartan having no effect in cell lines lacking AGTR1 due to transcriptional 
silencing, affirming the specificity of the effect. The ability of losartan to promote melanoma 
proliferation is in clear contrast to its anti-proliferative effect in breast cancer cells over-expressing 
AT1R (9, 10, 11) and to a study in murine melanoma cells (13). To the best of our knowledge, there 
are no previous reports that pharmacological blockade of AT1R promotes cancer cell growth. 
Second, targeted down-regulation of AGTR1 using inducible shRNA conferred increased ability to 
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proliferate in serum-free and low serum medium in cell lines expressing AGTR1 and thereby 
mimicked the effect of losartan. Again, we are not aware of previous evidence demonstrating this 
effect. Third, ectopic expression of AGTR1 in cell lines with transcriptional silencing of the 
endogenous gene resulted in cell death making it impossible to derive clones stably expressing 
AGTR1 from parental cells with no or low endogenous expression. However, no inhibitory effect on 
proliferation was seen in cell lines that express endogenous AGTR1. This effect was reproducibly 
observed in the absence of exogenous AngII and in both serum replete and serum-free conditions. 
These observations are consistent with a tumour suppressor function for AGTR1 that can occur in a 
ligand-independent manner. We note that ligand-independent activation of AT1R (and AT2R) is well-
recognised (25, 26). Fourth, AGTR1 expression is silenced by CpG island methylation in melanoma 
but not in control benign nevi. Transcriptional silencing in neoplastic but not equivalent normal 
tissue is a recognized feature of tumour suppressor genes and we are not aware of any previous 
reports of methylation-dependent transcriptional silencing of AGTR1 in cancer. The frequency with 
which AGTR1 is silenced implies strong selective pressure to abrogate the function of AT1R in 
advanced melanoma and is consistent with our functional analyses demonstrating that inactivation 
(either pharmacologically with losartan or by shRNA) confers a growth advantage to melanoma cells 
in allowing serum-free proliferation and with the proposed function of AGTR1 as a ligand-
independent tumour suppressor. The specificity of AGTR1 methylation for malignant melanocytes 
and its association with advanced / metastatic melanoma is also consistent with a tumour suppressor 
function for AT1R. 
Despite the negative growth regulatory effect of AGTR1, we show in this study that AngII 
nonetheless promotes serum-free proliferation in melanoma cell lines and we demonstrate several 
lines of evidence to support the hypothesis that this effect occurs via AT2R. First, AngII had no 
mitogenic effect on the serum-free proliferation of cell lines lacking expression of AT2R, as 
exemplified by comparison of SKMEL 23 and SKMEL224. In both cell lines expression of AGTR1 
is silenced by CpG island methylation whilst AT2R is expressed in SKMEL23 but not in SKMEL224 
and AngII promoted serum-free growth in SKMEL23 but not in SKMEL224. Furthermore, A375 
cells which, like SKMEL23, have a silenced AGTR1 but express AGTR2 also demonstrate growth 
promotion in serum-free conditions by AngII. Second, growth of melanoma cells expressing AGTR2 
was blocked by the AT2R selective antagonists PD123319 and EMA401. Third, Y6AII, a highly 
selective AT2R agonist (20) phenocopied the mitogenic effect of AngII but only in melanoma 
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expressing AT2R. Promotion of proliferation by Y6AII strongly supports our hypothesis that AngII 
acts as a mitogen in melanoma via AT2R and not AT1R.  Fourth, AGTR2 is over-expressed in several 
novel early passage cell lines established de novo in our laboratory from histologically confirmed 
melanoma CNS metastases. Given the low expression of AGTR2 in normal melanocytes, the frequent 
over-expression of AGTR2 implies that this confers a growth advantage in advanced melanoma. Of 
note, AGTR1 was undetectable in the majority of these cell lines, consistent with a model in which 
silencing of AGTR1 abrogates the ligand-independent growth suppressor effect of AGTR1 and over-
expression of AGTR2 promotes proliferation via ligand-dependent mechanisms. 
Together these mechanistic studies suggest that loss of AT1R confers a more aggressive phenotype to 
a subset of melanomas. Accordingly, the expression of AGTR1 was greatly decreased in metastatic 
relative to matched primary clinical melanomas and, conversely, AGTR1 methylation quantitatively 
increased in metastatic derivatives of primary clinical melanomas. We propose, therefore, a model in 
which the status of the RAS influences the biology of melanoma. In early disease, exemplified by the 
RGP cell line PMWK, AGTR1 is expressed and the clinical phenotype is typically not aggressive. 
With malignant progression, AGTR1 is silenced by CpG island methylation conferring a more 
aggressive phenotype (for example by allowing a proliferative advantage in low growth factor 
conditions), whereas AGTR2 is expressed and acts as the transducing receptor for the mitogenic 
effects of AngII. 
Our data have clear potential clinical implications. First, we have shown that blocking AT2R with the  
antagonists PD123319 and EMA401 inhibits proliferation of melanoma cells expressing AGTR2 in  
vitro and in vivo in a zebrafish model. The most robust inhibition was seen with EMA401. This  
agent is a first in class potent and highly selective antagonist of AT2R and is under clinical  
development to treat peripheral neuropathic pain (27). Whereas the effect of PD123319 was  
evident in the presence of exogenous AngII, EMA401 exhibited complete inhibition of melanoma  
proliferation in the absence of exogenous AngII. Of note, the anti-proliferative effects of AT2R  
blockade occurred in both BRAF V600 mutation positive, NRAS mutation positive and in double  
negative (BRAF & NRAS wild-type) cell lines implying that inhibition of AT2R may be a viable  
therapeutic strategy in melanomas lacking common driver mutations.  We also show that antagonism  
of AT2R potentiates the anti-proliferative effect of small molecule BRAF inhibitors. We demonstrate  
potentiation of dabrafenib in 4 independent BRAF V600 mutation positive, AT2R positive cell lines.  
Therapeutic synergy without additional toxicity implies that this combination may improve the  
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clinical utility of currently used anti-melanoma drugs. Studies to determine the optimal combinations  
of AT2R blockers with BRAF and MEK inhibitors using in vivo models are in progress.  Third, the  
ability of AngII to drive proliferation of melanoma implies that agents which reduce serum levels of  
AngII may have growth inhibitory activity. The Angiotensin Converting Enzyme inhibitors (ACEI)  
such as lisinopril and ramipril, although producing only incomplete inhibition of ACE (28), are  
widely used in cardiovascular medicine. Later generation agents that inhibit renin mediate substantial  
reductions in serum AngII levels (29). One such agent, Aliskiren, produces highly efficient reduction  
in serum AngII and has potent anti-hypertensive properties. It would be of interest to determine the  
effect of Aliskiren on melanoma growth in vivo. We show in our study that AGTR2 is over- 
expressed in early passage cell lines developed in our laboratory from CNS melanoma metastases.  
Importantly, the use of Aliskiren to deplete serum AngII as a potential therapeutic strategy for CNS  
melanoma metastasis would abrogate the requirement for passage of the drug across the blood : brain  
barrier.  
  
Indirect support for the hypothesis that AngII may promote cancer growth and that expression of  
AGTR1 may correlate with a better prognosis is afforded by the results of a number of 
epidemiological studies. Yoon et al (29) demonstrated a generalized decreased risk of cancer 
associated with use of AT1R blockers in cohort and nested case-control studies and in studies with 
long-term follow-up of more than five years. Critically however, in subgroup meta-analysis an 
increased risk specifically of melanoma and renal cancer was reported in patients using ATR 
blockers. Of note, AGTR1 is also subject to transcriptional silencing in metastatic clear cell 
carcinoma of the kidney (unpublished observations). In a study in lung cancer, low ACE levels were 
predictive of OS benefit from cediranib (30) and higher activity of the ACE-AngII-AGTR1 axis 
associated with a better response to bevacizumab in cancer (31). 
 
We have shown in the present study that methylation of AGTR1 is associated with metastatic 
melanoma. Furthermore, analysis of a series of patient-matched primary: metastatic melanomas 
demonstrated that methylation levels in the AGTR1 CpG island frequently increase in the progression 
of a primary cutaneous melanoma to a metastatic lesion. This association of AGTR1 CpG island 
methylation with metastatic disease was reflected in the presence of methylated genomic DNA in the 
peripheral blood of a subset of patients with metastatic disease, implying that detection may have 
utility as a biomarker, particularly of visceral and CNS metastatic disease. We are investigating this 
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possibility in large, prospectively collected series of sera with known clinical outcome analyzing 
AGTR1 both alone and in combination with TFPI2 (16). 
In conclusion, we show here that the status of the RAS is an important determinant of the biological 
properties of melanoma and may be exploitable both diagnostically and therapeutically. 
 
Materials and Methods 
 
Cell lines and drugs 
 
Melanoma cell lines were routinely grown as described previously (16). Primary cultures of brain 
metastatic melanomas M5, M78, M80 and M88 were established from fresh tumour tissue obtained 
from neurosurgical resection of intracranial lesions confirmed to be metastatic melanoma by 
histopathology. Tumours were washed in DMEM: F12 (1:1) (Gibco), minced through a cell strainer 
(BD Falcon) to obtain a single cell suspension and cells pelleted by centrifugation for 10mins at 12K 
rpm. The pellets were briefly re-suspended in 1ml of sterile dH20 to lyse contaminating red blood cells 
followed by the addition of 10ml of DMEM: F12 + 10% FBS to neutralise the effects of dH20. Cells 
were pelleted as before and cultured in fresh DMEM: F12 +10% FBS at 370C. The selective AT1R 
inhibitor losartan and the highly selective AT2R agonist Y6AII recently developed by us were 
synthesised as described previously (20). AngII and PD123319 were purchased from Sigma. EMA401, 
a highly selective tetrahydroisoquinoline AT2R antagonist (21), was kindly provided by Novartis 
pharmaceuticals. Demethylation experiments using azacytidine and trichostatin were done as 
described previously (33, 34). Dabrafenib was purchased from Sigma. 
 
Plasmid vectors and generation of stable clones 
 
To generate an AGTR1 expression vector, the AGTR1 ORF was purchased from Origene and sub-
cloned into pcDNA3-DEST40 using Invitrogen’s Gateway Technology to generate 
pcDNA3.2/V5/GW/AGTR1. pcDNA3.2/V5/GW/CAT served as the control plasmid. The sequence 
of both plasmids was verified by sequencing. The TRIPZ AGTR1 shRNA plasmids (set of 5) for 
inducible knockdown of AGTR1 and the non-silencing control plasmid were purchased from DE 
Dharmacon. Cells were transfected with 1ug of each of the plasmids using metafectine (Biontex) as 
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per manufacturer’s instructions and transfectants selected in 0.5µg/mL puromycin (Sigma). 
Expression of the AGTR1 or non-silencing shRNA was induced by adding 2 µg/mL doxycycline 
(Sigma) every 48 hours. Transfectants were analysed for knockdown of AGTR1 by qPCR and by 
Western blotting using the Novus Biologicals antibody (NBP-77078) at a dilution of 1:250.  
 
Proliferation analysis 
 
Cell proliferation was measured using the sulforhodamine b (SRB) colorimetric assay. Cells were 
seeded into 96 well plates (Costar) at a density of 4x103 cells per well in media containing 10% FCS. 
24hrs after plating culture media was replaced either with media containing 10% FBS (non-starved) 
or 0% FBS (starved). After a further 24hrs hours cells were treated with drugs as appropriate and 
incubated for various time points (D1, D3, D5) and harvested by fixing in 10% cold trichloroacetic 
acid (TCA) for at least 1 hour at 4°C. Fixed plates were washed 4 times with dH2O and air dried at 
room temperature prior to staining with 60 µL 0.4% SRB for 1h at RT. Unbound SRB was removed 
by washing plates 4 times using 0.1% acetic acid and allowed to air dry at room temperature. Bound 
SRB was re-suspended in 150µL 10 mmol/L Tris pH 10.5 and the absorbance read at 490nm using an 
ELx800 microplate reader (BioTek). 
 
Clonogenic Assays  
 
Clonogenic assays using transiently transfected cells were performed by plating 2x105 cells / 6cm dish 
and transfected after 24h with 1g of pcDNA3.2/V5/GW/AGTR1 or control vector 
pcDNA3.2/V5/GW/CAT using Metafectine (Biontex) according to the manufacturer’s instructions. 
Transfection efficiency was 25–30% under these conditions as measured by immunofluorescence 
staining using V5 antibody. Essentially transfected cells were fixed with 4% paraformaldehyde for 15 
minutes, permeabilized with 0.25% Triton™ X-100 for 10 minutes, and blocked with 5% BSA for 1 
hour at RT. The cells were labelled with V5 Tag Mouse Monoclonal Antibody (Invitrogen) at a dilution 
of 1:400 in 1% BSA and incubated for 3 hours at RT and then labelled with Rabbit Anti-mouse FITC 
Secondary Antibody (Sigma) at a dilution of 1:100 for 30 minutes at RT. Percentage of fluorescent 
cells was detected using a Nikon microscope at 20X magnification. 48 hours after transfection 
puromycin (0.5g/ml) was added and medium containing drug was replaced on day 3 and 5. On day 
8, cells were washed with PBS and fed with fresh medium without drug. Medium was replaced every 
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72–96 h for the remainder of the experiment. Cells were monitored daily by light microscopy for small 
colonies of proliferating cells. Colonies were counted 3–4 weeks after the removal of drug by staining 
with Coomassie Brilliant Blue. Cell clusters of 50 cells were defined as colonies.  
 
Angiogenesis assays 
 
To assess the role of angiotensin receptor signalling in the induction of tumour associated angiogenesis 
by melanoma cells, human microvascular endothelial cells (hCMEC/D3) were exposed to conditioned 
media (CM) collected from PMWK cells treated with angiotensin II alone or in combination with 
losartan and PD123319. To prepare conditioned medium (CM) PMWK cells were seeded onto 6 well 
plates (Corning, USA) at 1.5x105 cells per well and allowed to adhere for 24h. Cells were washed 
twice with warm PBS and media replaced with 2mL per well of EBM-2 basal medium without any 
supplements. The EBM-2 basal medium was conditioned for 24h, then carefully collected and 
centrifuged at 300 RCF for 5 minutes at RT to pellet cells and debris. The CM was moved to a fresh 
tube and used immediately in the endothelial cell tube formation assay of angiogenesis. To perform 
this assay, µ-slide angiogenesis slides (Ibidi, Germany) were coated with 10µL growth factor reduced 
matrigel (10 mg/mL, Corning, USA) per well using cooled pipette tips to prevent early polymerisation 
of the matrigel. Coated slides were then placed in 10cm dishes to prevent scratching and incubated at 
37°C for 30 min. During the incubation, hCMEC/D3 cells were washed twice with PBS, trypsinised 
and counted. hCMEC/D3 cells were aliquoted into sterile 1.5 mL micro-centrifuge tubes (Eppendorf, 
Germany) at 4x104 cells and pelleted by 5 min centrifugation at 300 RCF. Cell pellets were re-
suspended in 200µL CM and plated onto matrigel coated angiogenesis slides in triplicate (10000 cells 
in 50µL per well). This was done to ensure maximum exposure time of endothelial cells to the CM. 
Tube formation was monitored throughout the experiment and imaged at 6 hours post-plating using a 
TMS inverted phase contrast microscope (Nikon, Japan) with a DinoEye AM7023 eyepiece camera 
(Dino-Lite, Taiwan) at 2X magnification. Tube formation was analysed using the ImageJ angiogenesis 
analyser plugin (22). 
 
Zebrafish assays 
 
SKMEL23 cells were transplanted into 2-day-old casper zebrafish, Cells were stained prior to injection 
with cell tracker (CMTPX-Red, Molecular Probes) for 30min at 37°C and washed twice with PBS. 
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Later the cells were trypsinised and re-suspended in 500µl RPMI medium. The cells were incubated 
for 20 minutes on ice and 100 cells were injected into the yolk sac of 20-30 casper zebrafish/treatment 
(35). Following recovery for one hour at 28°C, zebrafish were maintained at 35°C, and screened for 
Red fluorescence at the injection site. At 48h post-injection the zebrafish were treated for 10 days with 
30µM PD or EMA401 in E3 medium (1mM NaCl, 0.17mM KCl, 0.33 mM CaCl2, 0.33mM MgSO4, 
10-5 % Methylene Blue). Tumour growth was assessed by fluorescent imaging every 48 hours.  
 
Clinical material 
 
The study was approved by the Local Research Ethical Committee, East London and City Health 
Authority and the Tayside Tissue Bank, under delegated authority from the Tayside Local Research 
Ethics Committee. Tissue for culture of CNS melanoma metastasis was obtained from Imperial 
College Tissue bank. Tissues and sera were used after informed consent had been obtained. In all 
cases, micro-dissection of tissue sections was performed to enrich for melanoma cells prior to 
isolation of nucleic acids. Benign pigmented nevi (n=8) from sun-exposed skin were used as control 
tissues. We used proteinase K digestion to isolate genomic DNA from all tissue sections. Sera were 
collected from patients (n=63) at the time of diagnosis of metastatic disease or during routine follow 
up. Sera were harvested using a standard operating procedure in which peripheral blood was subject 
to centrifugation immediately after venesection, then snap frozen in aliquots that were stored at -80o 
C. 200 l units of serum were thawed immediately prior to use and genomic DNA isolated using the 
QIAamp DNA Blood Mini kit (Qiagen, Germany) and DNA modified with sodium bisulphite as 
described below. 
 
Methylation analysis 
 
The 5´ end of AGTR1 contains a CpG island 
(http://www.ebi.ac.uk/Tools/emboss/cpgplot/index.html). Genomic DNA (1µg) was extracted and 
modified by sodium bisulphite as described previously (27, 28). Pyrosequencing was performed 
using the PyroMark ID System (Biotage) and primers were designed to cover a region including 7 
CpG dinucleotides of the CpG island. The primers were as follows: 5’- biotin- 
GTTAGGATTTTAGGTAGTAG -3’ (forward primer) and 5’- CTCCAACCACTCCCCAT -3’ 
(reverse primer), amplifying a 100bp region. PCR was performed in a final volume of 30µl, 
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containing 0.5µM of each primer, 200µmol/L of each dNTP, 0.05 units of AmpliTaq Gold 360 DNA 
polymerase in buffer containing 1.5mmol/L MgCl2, 3µl of 360GC enhancer (Applied biosystems) 
and 2µl of bisulphite-treated DNA as template. The initial denaturation step (95°C, 10 min) was 
followed by 35 cycles of 30 s at 95°C, 30 s at 53°C, 40 s at 72°C, and a final extension step at 72°C 
for 10 min. Three µl of the PCR products were visualised by gel electrophoresis and 25µl were 
subjected to pyrosequencing using the reverse as sequencing primer at a final concentration of 
0.5µM. Purification and subsequent processing of the biotinylated single-strand DNA was done 
according to the manufacturer’s instructions using the Pyro Gold reagents kit (Biotage). Resulting 
data were analyzed and quantified with the PyroMark CpG Software (Biotage). Positive (commercial 
methylated DNA) and negative (placenta DNA) controls were included and treated as well as 
samples. Pyrograms of the control DNA were analysed to confirm complete bisulfite conversion. 
Sera were deemed positive if the % methylation was  5 at 3 or more Methylation Variable Positions 
(MVP) in the amplified fragment of the CpG island. 
 
Gene expression analysis 
 
Total RNA was extracted using the RNeasy mini kit (Qiagen) according to the manufacturer’s 
instructions including the optional on-column DNase step. Total RNA was reverse transcribed using 
random primers (Invitrogen) following the M-MLV Reverse Transcriptase protocol (Promega) and 
cDNA was stored at -20°C until used. TaqMan® probe-based gene expression analysis (Applied 
Biosystems) was used to detect AGTR1 (assay ID: Hs00258938_m1) and AGTR2 (assay ID: 
Hs02621316_s1). qPCR reactions were carried out in triplicate following the manufacturers protocol 
on a C1000 Thermal Cycler combined with a CFX96 detection module (Bio-Rad). 50ng of template 
cDNA was used per reaction. No-template controls and no-RT controls were included in each run to 
exclude false positives due to impurities. Expression data was normalised to the mean Ct value of the 
reference genes TATA-binding protein (TBP) and hypoxanthine phosphoribosyltransferase 1 
(HPRT1) and displayed as 2-ΔCt.  
 
Statistics 
 
Statistical analyses were performed using Prism 5 (GraphPad software, Inc., La Jolla, CA, USA). The 
unpaired Mann-Whitney t-test was used to compare methylation levels between different groups for 
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both cell lines and tissue samples. Significant differences in proliferation were also established by 
unpaired t-test. 
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Figure Legends 
 
Figure 1. Expression of AGTR1 is silenced by CpG island methylation in melanoma.  
 
A: qPCR analysis of AGTR1 and AGTR2 in melanoma cell lines. Data shown are mean expression 
+/- 1SD from 2 experiments. B: Representative pyrograms of AGTR1 CpG island analysis in 
melanoma cell lines. Cell lines were subjected to pyrosequencing analysis as described in Methods. 
C: Summary of quantitative methylation analysis of AGTR1 CpG island. The number denotes each 
individual CpG dinucleotide in the amplified fragment analysed by pyrosequencing. Five levels of 
methylation are represented, the level of methylation increasing with increasing intensity of shading 
in the circles as indicated. D: Demethylation reactivates expression of AGTR1 in melanoma cell lines 
with transcriptional silencing. The indicated melanoma cell lines were grown in the presence of 
Trichostatin (T), Azacytidine (A) or both drugs (A & T). Expression of AGTR1 was determined by 
qPCR. Data shown are mean expression relative to untreated controls (C) +/- 1SD. 
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Figure 2. Methylation associated silencing of AGTR1 is associated with metastasis in 
melanoma.  
A: qPCR analysis of AGTR1 in paired primary : metastatic melanomas. The figure shows relative 
expression in 9 paired cases. Expression is down regulated in 7 of the 9 cases. In 3 cases expression 
was undetectable in the metastasis. For clarity of the figure these cases are shown as 0.01 relative 
expression.  B: Representative pyrograms of AGTR1 CpG island analysis in clinical cases of 
melanoma showing unmtheylated and methylated cases as indicated. C: AGTR1 CpG island 
methylation is increased in primary melanomas which metastasize and in metastatic lesions. 
Genomic DNA was isolated from benign nevi (N), primary melanomas (P1-P10) which were all of 
BT < 1mm and did not subsequently metastasise and from high-risk primary melanomas P11-16 and 
their matched, subsequent metastatic lesions (M11-M16). In all cases, pyrosequencing was 
performed as described in Methods. The degree of methylation at each analysed MVP is represented 
by the intensity of shading in the circles as shown in the figure. D: Methylated genomic DNA from 
the AGTR1 CpG island is detectable in the serum of patients with metastatic melanoma. The figure 
shows representative methylation profiles from 6 patients: 2 without metastatic disease (no 
metastases) and 4 with metastatic disease. The sites of metastases are: bone (Bo), lung (Lu), lymph 
node (LN) and sub-cutaneous (SC). The profiles show % CG methylation at each of 7 MVPs in the 
AGTR1 CpG island determined by pyrosequencing. E: Expression of AGTR1 and AGTR2 in early 
passage CNS metastatic melanoma cell lines is consistent with a tumour suppressor function for 
AGTR1 and oncogenic function for AGTR2. Novel CNS metastatic melanoma cell lines were derived 
as described in Methods and expression of AGTR1 and AGTR2 was assessed by qPCR. 
 
Figure 3. Antagonism of AT1R promotes melanoma proliferation 
  
The selective AT1R antagonist losartan promotes serum-free proliferation of the AGTR1-expressing 
melanoma cell line PMWK. PMWK cells were grown in serum-free medium without (control) or in 
the presence of 100M losartan and photographed after 96 hours. B: Growth promotion of PMWK 
and SKMEL147 cells by losartan occurs in serum-free medium. Cells were grown in medium 
containing 10% FBS or in serum-free conditions in the presence (black squares) or absence (empty 
circles) of 100M losartan as indicated. Cell numbers were estimated at various time points as 
described in Methods. Data shown are A490 values +/- 1SD. C: Losartan-dependent proliferation in 
serum-free conditions requires expression of AGTR1. PMWK and SKMEL224 cells were grown in 
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serum-free medium in the presence (black squares) or absence (clear circles) of 100M losartan as 
indicated and cell numbers estimated as above. Data shown are A490 values +/- 1SD. 
 
Figure 4. AGTR1 is a growth suppressor in melanoma but AngiotensinII promotes melanoma 
proliferation.  
 
A: Stable knock down of AGTR1 promotes low serum growth of PMWK cells. PMWK cells stably 
expressing the AGTR1 shRNA vector or non-silencing control vector were cultured in 10% FBS in 
the absence (-) or presence (+) of doxycycline (2g/ml) and knockdown of AGTR1 was assessed by 
qPCR after 48 hours (left hand figure) and western blotting (middle figure). Image analysis (right 
hand figure) confirms knock down. Cells stably expressing either the control plasmid (control) or 
AGTR1 knockdown plasmid (AGTR1) were then grown in 10% FBS, 2% FBS or 1% FBS in the 
absence (-) or presence (+) of doxycycline as shown and A490 determined after 72 hours. Data shown 
are mean A490 values +/- 1SD. C: Ectopic expression of AGTR1 inhibits proliferation in melanoma 
cells lacking endogenous expression. SKMEL224, SKMEL23 and PMWK cells were transfected 
with 0, 100 or 1000 ng of pcDNA3AGTR1 then grown in medium with 10% serum together with 
G418. Data shown are colony number +/- 1SD relative to cells receiving vector only from at least 
two experiments. D: Dose : response effect of AngII on proliferation of melanoma cell lines. The 
upper panel shows growth in 10% foetal bovine serum in which exogenous AngII has no effect on 
proliferation. The lower panel shows growth in 0% serum in which the proliferation of PMWK and 
SKMEL23, but not that of SKMEL224, is promoted in a dose-dependent manner by AngII. Cell 
lines were grown in the presence of the indicated concentrations of AngII and proliferation 
determined as described in Methods. Data shown are mean A490 values +/- 1SD. E: Y6AII, a potent 
and highly specific agonist of AT2R, promotes serum-free proliferation of cells expressing AGTR2. 
PMWK cells were grown in serum-free medium in the presence of increasing concentrations of 
Y6AII or 100 pM AngII as indicated and proliferation assessed. UC1: at start of experiment; UC5: 
untreated control after 5 days. Data shown are A490 values +/- 1SD.  
 
Figure 5. Inhibition of AT2R suppresses proliferation of melanoma cell lines 
 
A: Effect of PD123319 on proliferation of melanoma cell lines. PMWK (AGTR1 + / AGTR2 +), 
SKMEL23 (AGTR1 - / AGTR2 +) and SKMEL 224 (AGTR1 - / AGTR2 -) cells were grown in 
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either 10% serum (left hand panels) or 0% serum (right hand panels). Cells grown in 0% serum were 
either untreated control cells (clear circles), treated with AngII (A, black squares) or AngII + 
PD123319 (A + PD123319, black diamonds).  B: Suppression of proliferation of AGTR2 expressing 
melanoma cells by inhibition of AT2R. SKMEL23 cells were grown in medium containing1% serum 
in the absence of exogenous AngII but in the presence of varying concentrations of either PD123319 
or EMA401 as shown and cell numbers estimated by measurement of A490. C: AT2R blockade 
inhibits melanoma growth in vivo. SKMEL23 cells were injected into Zebrafish yolksac as described 
in Methods. -: control fish not injected; +U injected but untreated control; +EMA injected and grown 
in the presence of 30M EMA. 
 
Figure 6. Antagonism of AT2R inhibits proliferation and angiogenesis and potentiates targeted 
therapy in melanoma.  
 
A: Blocking AT2R inhibits angiogenesis. Angiogenesis assays in PMWK and SKMEL23 cells were 
performed as described in Methods. The upper panels show representative appearances of SKMEL23 
untreated controls (UC) and cells exposed to EMA401 and the lower panels PMWK untreated 
controls (UC) and cells exposed to PD123319. B: Quantitative analysis of total segment length 
(upper panels) and number of meshes (lower panels). PMWK and SKMEL23 cells were treated in 
the indicated way (CM: conditioned medium; AngII: 100 pM angiotensinII; LOS: 100M losartan; 
PD30: 30M PD123319; Y6: 100M Y6AII; EMA30: 30M EMA401). Data are mean +/- 1SD. C: 
Effect of AT2R antagonism on sensitivity to BRAF inhibition in melanoma. SKMEL23 (BRAF wild-
type), A375, WM164 and WM793 (all BRAF V600 mutation positive) cells were grown in 1% serum 
in the presence of EMA401 (M), dabrafenib (5nM) or both agents as shown and cell numbers 
directly counted. Data shown are mean relative cell number +/- 1SD from 2 independent 
experiments. 
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As previously published, direct treatment of hCMEC/D3 cells with an AGTR1 inhibitor enhances tube
formation (Alhusban et al., 2013). On the other hand both Losartan and PD123319 are anti-angiogenic
when used to treat PMWK (ie. Indirect effect on angiogenesis). Double blockade (Los+PD) further
enhances this effect.
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Table 1 
 
Cell line Description     BRAF / NRAS  AGRT1 % methylation  U or M 
 
HEMA  Normal human melanocytes   Wt / Wt   3   U 
HEMN1 Normal human melanocytes   wt / Wt   1   U 
SBCL2  Radial growth phase melanoma  Wt / Q61L   6   U 
PMWK  Radial growth phase melanoma  Wt / Wt   2   U 
WM35  Radial growth phase melanoma  V600E / Wt   15   U 
WM-902.6 Vertical growth phase melanoma  V600E / Wt   1   U   
SKMel224 Vertical growth phase melanoma  Wt / Q61R   35   M 
SKMEL505 Vertical growth phase melanoma  Wt / Wt   94   M 
WM-266.4 Metastatic melanoma    V600D / Wt   9   U 
SKMEL2 Metastatic melanoma    Wt / Q61R   22   M 
SKMEL23 Metastatic melanoma    G466A / Wt   94   M 
SKMEL30 Metastatic melanoma    Wt / Q61R   90   M 
SKMEL147 Metastatic melanoma    Wt / Q61R   3   U 
SKMEL173 Metastatic melanoma    Wt / Q61K   41   M 
SKMEL501 Metastatic melanoma    V600E / Wt   2   U 
COLO-829 Metastatic melanoma    V600E / Wt   19   U 
C8161  Metastatic melanoma    Wt / Wt   24   M 
WM-239A Metastatic melanoma    V600D / Wt   7   U 
A375M Metastatic melanoma    V600E / Wt   3   U 
 
 
Abbreviations Wt: wild-type; U: unmethylated; M: methylated.    
 
